Core Scientific Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021
Cash & Equivalents	69.71	52.24	131.68
Short-Term Investments	2.28	0.72	234.3
Cash & Cash Equivalents	71.99	52.96	365.98
Cash Growth	35.93%	-85.53%	-
Receivables	1	0.26	1.68
Other Current Assets	24.02	31.88	388.9
Total Current Assets	97.02	85.1	756.56
Property, Plant & Equipment	593.28	711.56	597.3
Goodwill and Intangibles	2.25	1.7	1,064
Other Long-Term Assets	19.62	9.32	21.05
Total Long-Term Assets	615.14	722.58	1,682
Total Assets	712.16	807.69	2,439
Accounts Payable	154.75	53.64	11.62
Deferred Revenue	9.83	78.19	136.36
Current Debt	144.21	37.01	104.45
Other Current Liabilities	179.64	17.95	67.86
Total Current Liabilities	488.42	186.79	320.29
Long-Term Debt	820.67	1,028	714.36
Other Long-Term Liabilities	0	2.21	18.53
Total Long-Term Liabilities	820.67	1,030	732.89
Total Liabilities	1,309	1,217	1,053
Total Debt	964.88	1,065	818.81
Debt Growth	-9.40%	30.07%	-
Retained Earnings	-2,420.24	-2,173.75	-27.43
Comprehensive Income	0	0	-10.97
Shareholders' Equity	-596.94	-409.35	1,341
Net Cash / Debt	-892.89	-1,012.08	-452.83
Net Cash Per Share	-2.35	-2.97	-1.94
Working Capital	-391.41	-101.69	436.27
Book Value Per Share	-1.57	-1.20	6.47

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).